Skip to Content

Join the 'Sargramostim' group to help and get support from people like you.

Sargramostim News

Combo Treatment for Advanced Melanoma Seems to Improve Survival

Posted 4 Nov 2014 by Drugs.com

TUESDAY, Nov. 4, 2014 – Patients with advanced melanoma may live longer when treated with a combination of the cancer drug Yervoy and the immune system booster sargramostim, a new study finds. Patients given the two drugs had a median survival of 17.5 months, compared to 12.7 months for those on Yervoy (ipilimumab) alone. At one year, overall survival was nearly 69 percent for those on the combination therapy, versus 53 percent for those on Yervoy alone, the researchers said. "Patients did live longer, as well as having less serious side effects, when given the combination," said lead researcher Dr. F. Stephen Hodi, an assistant professor of medicine at the Dana-Farber Cancer Institute in Boston. Melanoma is the most serious form of skin cancer. In the United States, more than 12,000 people die from advanced melanoma each year, the U.S. Centers for Disease Control and Prevention ... Read more

Related support groups: Melanoma, Yervoy, Leukine, Sargramostim

Ask a Question

Further Information

Related Condition Support Groups

Neutropenia Associated with Chemotherapy, Bone Marrow Transplantation, Myeloid Reconstruction, Bone Marrow Transplantation, Failure or Engraftment Delay, Bone Marrow Transplantation, Aplastic Anemia

Related Drug Support Groups

Leukine

Sargramostim Patient Information at Drugs.com